Format

Send to

Choose Destination
Am J Transplant. 2019 Mar;19(3):790-800. doi: 10.1111/ajt.15080. Epub 2018 Sep 22.

Effects of marine n-3 fatty acid supplementation in renal transplantation: A randomized controlled trial.

Author information

1
Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
2
Department of Renal Medicine, Akershus University Hospital, Lørenskog, Norway.
3
Department of Pathology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
4
Metabolic and Renal Research Group, UiT The Arctic University of Norway, Tromsø, Norway.
5
Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.
6
Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
7
Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway.
8
Department of Pharmacology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
9
Department of Radiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
10
Institute of Clinical Medicine, The University of Oslo, Oslo, Norway.

Abstract

Marine n-3 fatty acids (FAs) may exert beneficial effects on inflammation, fibrosis, and endothelial function, which could preserve renal graft function. In this randomized controlled trial, 132 Norwegian renal transplant recipients received either 2.6 g of marine n-3 FAs or olive oil (control) daily for 44 weeks, in addition to standard care. Thirty patients did not complete the trial. The primary endpoint was change (Δ) in measured glomerular filtration rate (mGFR) during follow-up. We found no significant difference in Δ mGFR between the marine n-3 FA group and controls (6.7 vs 3.8 mL/min per 1.73 m2 , P = .15). Significant beneficial effects from marine n-3 FA supplementation were, however, seen in secondary endpoints plasma triglycerides, plasma high-sensitivity C-reactive protein, and brachial artery flow-mediated dilation. In the per-protocol population, the renal graft indices percent interstitial fibrosis and Chronic Allograft Damage Index also were significantly lower in the marine n-3 FA group. The cumulative incidence of adverse events did not differ between the marine n-3 FA group (n = 218) and controls (n = 240). In conclusion, marine FA supplementation did not improve renal function compared with controls, but was safe, lowered plasma triglyceride and high-sensitivity C-reactive protein levels, and improved endothelial function (Clinical.Trials.gov identifier NCT01744067).

KEYWORDS:

clinical research/practice; interstitial fibrosis and tubular atrophy; kidney (allograft) function/dysfunction; kidney transplantation/nephrology; nutrition; pathology/histopathology; vascular biology

PMID:
30125457
DOI:
10.1111/ajt.15080

Supplemental Content

Full text links

Icon for Wiley Icon for Norwegian BIBSYS system
Loading ...
Support Center